'Multidisciplinary System at Hwasun Chonnam National University Hospital with Collaboration of Over 20 Medical Professionals'

Determining Personalized Treatment Plans for Each Patient... Increasing Patient Trust and Satisfaction

The multidisciplinary treatment system of Hwasun Chonnam National University Hospital, which performs the roles and functions of a nationally designated cancer center, is gaining attention.

In particular, the Lung Cancer Multidisciplinary Treatment Team, responsible for the treatment, prevention, and research of lung cancer, which is recognized as the leading cause of cancer death not only in Korea but worldwide, is making great achievements by providing customized treatment methods to patients with the collaboration of over 20 medical professionals.

According to Hwasun Chonnam National University Hospital on the 25th, the Lung Cancer Multidisciplinary Treatment Team holds weekly multidisciplinary consultation treatments with specialists from departments including ▲Pulmonology ▲Thoracic Surgery ▲Radiation Oncology ▲Radiology ▲Nuclear Medicine ▲Pathology ▲Neurosurgery to provide rapid diagnosis and the best treatment tailored to the patient's characteristics.

Since the hospital's opening, multidisciplinary collaborative meetings have been continuously held twice a week, with over 1,500 sessions conducted to date, establishing the meetings not only as a platform for treatment but also as an exemplary educational venue for young medical staff.

Formed in 2022, the multidisciplinary face-to-face treatment team, led by Head Professor Oh In-jae, includes Pulmonology’s Oh Hyung-joo, Thoracic Surgery’s Yoon Ju-sik, and Radiation Oncology’s Kim Yong-hyup, who directly meet with patients and their families to discuss test results and treatment plans.

Last year, about 30% of all newly diagnosed lung cancer patients at Hwasun Chonnam National University Hospital received multidisciplinary face-to-face treatment, which is more than twice the target rate (12.6%) suggested by the cancer adequacy evaluation.

As specialists from various fields gather ideas, the multidisciplinary treatment team’s joint research achievements are also shining.

Professor Oh In-jae was recognized for his research achievements utilizing the Hwasun Chonnam National University Hospital Human Bioresource Bank (Biobank) and received a commendation from the Director of the Korea Disease Control and Prevention Agency at the ‘Human Bioresource Bank Project Symposium’ held in November last year.

Over the past four years, he has collected more than 1,000 human bioresources (tissues, blood, and other specimens) from lung cancer patients to build a research foundation, earning recognition for publishing numerous international scientific and technological papers indexed in the Science Citation Index Expanded (SCIE).

This year, he published research on the immunotherapy results of durvalumab after concurrent chemoradiotherapy in Korean patients with stage III non-small cell lung cancer (NSCLC) (paper title: Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR) in the Journal of Thoracic Oncology (impact factor 20.121).

Recently, based on the findings from his research, he also participated in the publication of the book Artificial Intelligence in Thoracic Disease. This book includes various artificial intelligence research results, including the concordance rate between clinical decision support systems using AI and the multidisciplinary lung cancer collaborative treatment outcomes at Hwasun Chonnam National University Hospital.

Professor Oh In-jae stated, “Going forward, the lung cancer multidisciplinary treatment team will continue to operate with the mindset of a one team, delivering high-quality treatment and research activities befitting a world-class cancer hospital.”

This content was produced with the assistance of AI translation services.